94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Genet.
Sec. Epigenomics and Epigenetics
Volume 16 - 2025 | doi: 10.3389/fgene.2025.1522622
This article is part of the Research Topic Epigenetic Alterations in Tumors and Therapeutic Resistance View all 3 articles
Review of the Role and Potential Clinical Value of m6A Methylation Modifications in the Biological Process of Osteosarcoma
Provisionally accepted
Huaqiang Zhou 1
Rongbing Shu 1* Jianming Wu 1* Jiangjun Zhou 2* Zhuanyi Yu 3* Qiuxin Chen 3* Zhihao Peng 3* Min Zhao 3*- 1 Department of orthopaedic surgery, Yingtan People's Hospital, Yingtan, China
- 2 908th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Nanchang, Jiangxi Province, China
- 3 Yingtan People's Hospital, Yingtan, China
Osteosarcoma (OS), an aggressive bone tumor, is a substantial threat to the quality of life and survival of affected individuals. Despite recent improvements in OS therapies, the considerable variability and chemotherapy resistance of this cancer necessitate continuous research to discover new treatment targets and biomarkers.Recent epigenetic advances highlight the crucial role of N6-methyladenosine (m6A) methylation in cancer. In OS, m6A methylation has been demonstrated to be a pivotal component in the pathogenesis. This review introduces new findings regarding the association between m6A methylation regulators and OS, and summarizes the potential clinical applications of OS and m6A methylation regulators, including the role of m6A methylation in OS proliferation, growth, apoptosis, and cell migration, invasion, and metastasis; relationship between m6A methylation and OS chemotherapy resistance; and relationship between m6A methylation and OS prognosis. Our review had certain limitations. The interaction between m6A methylation regulators and other oncogenic factors, such as lncRNAs and ncRNAs, is not fully understood. We hope that these potential methods will be translated into clinical applications and effective treatment.
Keywords: m6A modification, Osteosarcoma, RNA methylation, epigenetics, writer, Eraser, Reader
Received: 04 Nov 2024; Accepted: 17 Feb 2025.
Copyright: © 2025 Zhou, Shu, Wu, Zhou, Yu, Chen, Peng and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Rongbing Shu, Department of orthopaedic surgery, Yingtan People's Hospital, Yingtan, China
Jianming Wu, Department of orthopaedic surgery, Yingtan People's Hospital, Yingtan, China
Jiangjun Zhou, 908th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Nanchang, 330002, Jiangxi Province, China
Zhuanyi Yu, Yingtan People's Hospital, Yingtan, China
Qiuxin Chen, Yingtan People's Hospital, Yingtan, China
Zhihao Peng, Yingtan People's Hospital, Yingtan, China
Min Zhao, Yingtan People's Hospital, Yingtan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.